TREKSTOR
16.12.2020 13:51:10 CET | Business Wire | Press release
With the end of the pandemic not in sight yet, TREKSTOR is announcing the expansion of its mask portfolio, therefore fulfilling the increased demand created by regulations and customers alike.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005568/en/
Some of the new entries are comprised of so-called filtering half-masks, commonly known as FFP2 and FFP3. The FFP2 masks with the model name BL-03N (item 30604) are packaged 2pcs per bag with the user manual directly printed on the outside. Comprised of 5 layers, the respirators have been type-approved by notified body SGS Fimko (0598) and are valid to use for 24 months from production. They are worn with ear-straps and come with a flexible nose guard included in the fabric.
Additionally, newly available are 20pcs boxes of two FFP3 masks with the model names LT-2020AP3 (item 30613) and LT-2020AP3V (item 30614), the later which includes a vent. Both masks are foldable, also include a nose-guard and are worn with elastic headbands, that can be adjusted to fit perfectly. Like all FFP3 masks, they filter ≥99% of particles, as has been confirmed by the notified body Applus (0370). This allows them to also be used in direct contact with COVID-19 positive patients.
„The demand for filtering half-masks has increased drastically over the last few weeks“ , says Shimon Szmigiel, CEO of TREKSTOR. „Therefore, we decided to expand our portfolio beyond the already available KN95 respirators with CE approval based on EU guideline PPE-R 02.075.“
At the same time the face mask portfolio was updated. While the focus always has been on EN 14683:2019 certified masks of both types IIR and I, they were always only available for adults. But now TREKSTOR also offers type IIR face masks for children as well.
„Type IIR face masks filter ≥98% of exhaled air, therefore offering good protection for everyone around“ , Simon Wiedemann, Head of Product Management explains. „With infections spreading in schools and day care centres more and more, wearing such masks consistently can help stop the spread of the virus dramatically.“
So kids can enjoy wearing a mask, TREKSTOR decided to offer them in 10 different designs, 5 each suited for boys and girls. Each design is packed 5pcs per re-sealable bag, if kids like to be surprised, the masks are also available in 5pcs mix packs with one mask of each design present within.
The kids masks are already in stock and can be ordered online at www.blnk-healthcare.com . The shop is also ready to accept pre-orders to FFP2 and FFP3 masks, which will then be fulfilled in early January. Interested parties can also declare their interest by sending an email to sales@blnk-healthcare.com . PR requests should be directed to pr@blnk-healthcare.com .
About TREKSTOR / blnk Healthcare
TREKSTOR, known as one of Europe’s leading consumer electronics manufacturers based in Bensheim, Germany, has been active in the healthcare space with its brand blnk starting March 2020, helping to stop the spread of the virus via face masks, disinfectants and other protective equipment. The company is selling equally to government institutions and the army alongside direct sales to care facilities, hospitals, pharmacies and end-consumers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005568/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom